KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Inventory (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Inventory for 12 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory fell 5.24% year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Dec 2025, down 5.24%, and an annual FY2025 reading of $5.9 million, down 5.24% over the prior year.
  • Inventory was $5.9 million for Q4 2025 at Travere Therapeutics, up from $5.5 million in the prior quarter.
  • Across five years, Inventory topped out at $20.8 million in Q3 2023 and bottomed at $3.9 million in Q1 2025.
  • Average Inventory over 5 years is $7.6 million, with a median of $6.6 million recorded in 2021.
  • The sharpest move saw Inventory surged 184.68% in 2023, then tumbled 69.4% in 2024.
  • Year by year, Inventory stood at $7.3 million in 2021, then tumbled by 38.15% to $4.5 million in 2022, then soared by 108.05% to $9.4 million in 2023, then tumbled by 34.11% to $6.2 million in 2024, then dropped by 5.24% to $5.9 million in 2025.
  • Business Quant data shows Inventory for TVTX at $5.9 million in Q4 2025, $5.5 million in Q3 2025, and $4.1 million in Q2 2025.